ReviewDevelopmental medicine and child neurology2026
Genomics and epilepsy: Opportunities to improve understanding and management.
Review in Developmental medicine and child neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genomics and epilepsy: Opportunities to improve understanding and management.Developmental medicine and child neurology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genomics has advanced our understanding of epilepsy through the discovery of the causes of many hundreds of different individual syndromes and the discovery of common variants contributing to the epilepsy risk. Many genomic research studies and clinical genetic laboratories now use advanced sequencing methods, including whole-genome sequencing studies. Such work generates significant amounts of data beyond a possible causal variant alone and can contain information about more complicated genomic contributions to the phenotype, including oligogenic and polygenic influences, modifiers, risk factors for traits such as postictal psychosis, and pharmacogenomic variants of importance to adverse reactions. Extraction of such data will help improve the characterization of each individual's epilepsy, potentially from diagnosis onwards. Newer methods, such as single-cell studies and combinations of genomic data with other data types are now being used. Genomics may also help protect people with epilepsy from climate change challenges. Opportunities from genomics will continue to enhance our understanding and management of epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.